Neoantigen Cancer Vaccine Market - Global Outlook and Forecast 2021-2027
Report Code: KNJ687726 No. of Pages: 101 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of Neoantigen Cancer Vaccine in Global, including the following market information: Global Neoantigen Cancer Vaccine Market Revenue, 2016-2021, 2022-2027, ($ millions) Global top five companies in 2020 (%) The global Neoantigen Cancer Vaccine market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neoantigen Cancer Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment: Global Neoantigen Cancer Vaccine Market, By Type, 2016-2021, 2022-2027 ($ millions) Global Neoantigen Cancer Vaccine Market Segment Percentages, By Type, 2020 (%) Personalized Vaccine Off-the-shelf Neovaccines China Neoantigen Cancer Vaccine Market, By Application, 2016-2021, 2022-2027 ($ millions) China Neoantigen Cancer Vaccine Market Segment Percentages, By Application, 2020 (%) Hospital Clinic Others Global Neoantigen Cancer Vaccine Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) Global Neoantigen Cancer Vaccine Market Segment Percentages, By Region and Country, 2020 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & Africa Competitor Analysis The report also provides analysis of leading market participants including: Total Neoantigen Cancer Vaccine Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions) Total Neoantigen Cancer Vaccine Market Competitors Revenues Share in Global, by Players 2020 (%) Further, the report presents profiles of competitors in the market, including the following: Roche Medimmune Merck Advaxis Agenus Genocea Gritstone Oncology Neon Therapeutics Nouscom OSE Immunotherapeutics Medigene Vaccibody Brightpath Biotherapeutics Geneos Therapeutics
1 Introduction to Research & Analysis Reports
1.1 Neoantigen Cancer Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neoantigen Cancer Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neoantigen Cancer Vaccine Overall Market Size
2.1 Global Neoantigen Cancer Vaccine Market Size: 2021 VS 2027
2.2 Global Neoantigen Cancer Vaccine Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neoantigen Cancer Vaccine Players in Global Market
3.2 Top Global Neoantigen Cancer Vaccine Companies Ranked by Revenue
3.3 Global Neoantigen Cancer Vaccine Revenue by Companies
3.4 Top 3 and Top 5 Neoantigen Cancer Vaccine Companies in Global Market, by Revenue in 2020
3.5 Global Companies Neoantigen Cancer Vaccine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neoantigen Cancer Vaccine Players in Global Market
3.6.1 List of Global Tier 1 Neoantigen Cancer Vaccine Companies
3.6.2 List of Global Tier 2 and Tier 3 Neoantigen Cancer Vaccine Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Neoantigen Cancer Vaccine Market Size Markets, 2021 & 2027
4.1.2 Personalized Vaccine
4.1.3 Off-the-shelf Neovaccines
4.2 By Type - Global Neoantigen Cancer Vaccine Revenue & Forecasts
4.2.1 By Type - Global Neoantigen Cancer Vaccine Revenue, 2016-2021
4.2.2 By Type - Global Neoantigen Cancer Vaccine Revenue, 2022-2027
4.2.3 By Type - Global Neoantigen Cancer Vaccine Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neoantigen Cancer Vaccine Market Size, 2021 & 2027
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Neoantigen Cancer Vaccine Revenue & Forecasts
5.2.1 By Application - Global Neoantigen Cancer Vaccine Revenue, 2016-2021
5.2.2 By Application - Global Neoantigen Cancer Vaccine Revenue, 2022-2027
5.2.3 By Application - Global Neoantigen Cancer Vaccine Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Neoantigen Cancer Vaccine Market Size, 2021 & 2027
6.2 By Region - Global Neoantigen Cancer Vaccine Revenue & Forecasts
6.2.1 By Region - Global Neoantigen Cancer Vaccine Revenue, 2016-2021
6.2.2 By Region - Global Neoantigen Cancer Vaccine Revenue, 2022-2027
6.2.3 By Region - Global Neoantigen Cancer Vaccine Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Neoantigen Cancer Vaccine Revenue, 2016-2027
6.3.2 US Neoantigen Cancer Vaccine Market Size, 2016-2027
6.3.3 Canada Neoantigen Cancer Vaccine Market Size, 2016-2027
6.3.4 Mexico Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Neoantigen Cancer Vaccine Revenue, 2016-2027
6.4.2 Germany Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4.3 France Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4.4 U.K. Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4.5 Italy Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4.6 Russia Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4.7 Nordic Countries Neoantigen Cancer Vaccine Market Size, 2016-2027
6.4.8 Benelux Neoantigen Cancer Vaccine Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Neoantigen Cancer Vaccine Revenue, 2016-2027
6.5.2 China Neoantigen Cancer Vaccine Market Size, 2016-2027
6.5.3 Japan Neoantigen Cancer Vaccine Market Size, 2016-2027
6.5.4 South Korea Neoantigen Cancer Vaccine Market Size, 2016-2027
6.5.5 Southeast Asia Neoantigen Cancer Vaccine Market Size, 2016-2027
6.5.6 India Neoantigen Cancer Vaccine Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Neoantigen Cancer Vaccine Revenue, 2016-2027
6.6.2 Brazil Neoantigen Cancer Vaccine Market Size, 2016-2027
6.6.3 Argentina Neoantigen Cancer Vaccine Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, 2016-2027
6.7.2 Turkey Neoantigen Cancer Vaccine Market Size, 2016-2027
6.7.3 Israel Neoantigen Cancer Vaccine Market Size, 2016-2027
6.7.4 Saudi Arabia Neoantigen Cancer Vaccine Market Size, 2016-2027
6.7.5 UAE Neoantigen Cancer Vaccine Market Size, 2016-2027
7 Players Profiles
7.1 Roche
7.1.1 Roche Corporate Summary
7.1.2 Roche Business Overview
7.1.3 Roche Neoantigen Cancer Vaccine Major Product Offerings
7.1.4 Roche Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.1.5 Roche Key News
7.2 Medimmune
7.2.1 Medimmune Corporate Summary
7.2.2 Medimmune Business Overview
7.2.3 Medimmune Neoantigen Cancer Vaccine Major Product Offerings
7.2.4 Medimmune Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.2.5 Medimmune Key News
7.3 Merck
7.3.1 Merck Corporate Summary
7.3.2 Merck Business Overview
7.3.3 Merck Neoantigen Cancer Vaccine Major Product Offerings
7.3.4 Merck Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.3.5 Merck Key News
7.4 Advaxis
7.4.1 Advaxis Corporate Summary
7.4.2 Advaxis Business Overview
7.4.3 Advaxis Neoantigen Cancer Vaccine Major Product Offerings
7.4.4 Advaxis Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.4.5 Advaxis Key News
7.5 Agenus
7.5.1 Agenus Corporate Summary
7.5.2 Agenus Business Overview
7.5.3 Agenus Neoantigen Cancer Vaccine Major Product Offerings
7.5.4 Agenus Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.5.5 Agenus Key News
7.6 Genocea
7.6.1 Genocea Corporate Summary
7.6.2 Genocea Business Overview
7.6.3 Genocea Neoantigen Cancer Vaccine Major Product Offerings
7.6.4 Genocea Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.6.5 Genocea Key News
7.7 Gritstone Oncology
7.7.1 Gritstone Oncology Corporate Summary
7.7.2 Gritstone Oncology Business Overview
7.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Major Product Offerings
7.4.4 Gritstone Oncology Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.7.5 Gritstone Oncology Key News
7.8 Neon Therapeutics
7.8.1 Neon Therapeutics Corporate Summary
7.8.2 Neon Therapeutics Business Overview
7.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.8.4 Neon Therapeutics Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.8.5 Neon Therapeutics Key News
7.9 Nouscom
7.9.1 Nouscom Corporate Summary
7.9.2 Nouscom Business Overview
7.9.3 Nouscom Neoantigen Cancer Vaccine Major Product Offerings
7.9.4 Nouscom Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.9.5 Nouscom Key News
7.10 OSE Immunotherapeutics
7.10.1 OSE Immunotherapeutics Corporate Summary
7.10.2 OSE Immunotherapeutics Business Overview
7.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.10.4 OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.10.5 OSE Immunotherapeutics Key News
7.11 Medigene
7.11.1 Medigene Corporate Summary
7.11.2 Medigene Business Overview
7.11.3 Medigene Neoantigen Cancer Vaccine Major Product Offerings
7.11.4 Medigene Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.11.5 Medigene Key News
7.12 Vaccibody
7.12.1 Vaccibody Corporate Summary
7.12.2 Vaccibody Business Overview
7.12.3 Vaccibody Neoantigen Cancer Vaccine Major Product Offerings
7.12.4 Vaccibody Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.12.5 Vaccibody Key News
7.13 Brightpath Biotherapeutics
7.13.1 Brightpath Biotherapeutics Corporate Summary
7.13.2 Brightpath Biotherapeutics Business Overview
7.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.13.4 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.13.5 Brightpath Biotherapeutics Key News
7.14 Geneos Therapeutics
7.14.1 Geneos Therapeutics Corporate Summary
7.14.2 Geneos Therapeutics Business Overview
7.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Major Product Offerings
7.14.4 Geneos Therapeutics Neoantigen Cancer Vaccine Revenue in Global (2016-2021)
7.14.5 Geneos Therapeutics Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables and Figures
Ask Sample Report to get more details… NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com